Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis

David Gillis; Nir Yetiv; Michael Gdalevich; Daniel Mimouni; Isaac Ashkenazi; Ofer Shpilberg; Arieh Eldad; Joshua Shemer

doi:10.1016/S0264-410X(00)00091-8

Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis

David Gillis, Nir Yetiv, Michael Gdalevich, Daniel Mimouni, Isaac Ashkenazi, Ofer Shpilberg, Arieh Eldad, Joshua Shemer

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. Copyright (C) 2000 Elsevier Science Ltd.

Original language	English
Pages (from-to)	3005-3010
Number of pages	6
Journal	Vaccine
Volume	18
Issue number	26
DOIs	https://doi.org/10.1016/S0264-410X(00)00091-8
State	Published - 1 Jul 2000
Externally published	Yes

Keywords

Hepatitis A
Immune Serum Globulin
Inactivated HAV vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(00)00091-8

Cite this

@article{ecdeaf02bea74041897fb3a737e38f80,

title = "Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis",

abstract = "We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. Copyright (C) 2000 Elsevier Science Ltd.",

keywords = "Hepatitis A, Immune Serum Globulin, Inactivated HAV vaccine",

author = "David Gillis and Nir Yetiv and Michael Gdalevich and Daniel Mimouni and Isaac Ashkenazi and Ofer Shpilberg and Arieh Eldad and Joshua Shemer",

year = "2000",

month = jul,

day = "1",

doi = "10.1016/S0264-410X(00)00091-8",

language = "English",

volume = "18",

pages = "3005--3010",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "26",

}

TY - JOUR

T1 - Active versus passive immunization against hepatitis A in the Israel defence forces

T2 - A cost-benefit analysis

AU - Gillis, David

AU - Yetiv, Nir

AU - Gdalevich, Michael

AU - Mimouni, Daniel

AU - Ashkenazi, Isaac

AU - Shpilberg, Ofer

AU - Eldad, Arieh

AU - Shemer, Joshua

PY - 2000/7/1

Y1 - 2000/7/1

N2 - We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. Copyright (C) 2000 Elsevier Science Ltd.

AB - We compared cost-benefit and cost-effectiveness analyses of hepatitis A prevention with immune serum globulin (ISG) vs inactivated hepatitis A vaccine (iHAV) in the Israel Defence Forces. Personnel were grouped according to conditions and duration of service and analyses were performed based on maximum and minimum hepatitis A projected incidences for each group. For standing army soldiers in field units, iHAV is economically superior compared with ISG. For the five other groups studied, the reverse is true. Expected increases in production costs of ISG and expected decreases in costs of iHAV are likely to make iHAV more economical in the future. Copyright (C) 2000 Elsevier Science Ltd.

KW - Hepatitis A

KW - Immune Serum Globulin

KW - Inactivated HAV vaccine

UR - http://www.scopus.com/inward/record.url?scp=0034237438&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00091-8

DO - 10.1016/S0264-410X(00)00091-8

M3 - Article

AN - SCOPUS:0034237438

SN - 0264-410X

VL - 18

SP - 3005

EP - 3010

JO - Vaccine

JF - Vaccine

IS - 26

ER -

Active versus passive immunization against hepatitis A in the Israel defence forces: A cost-benefit analysis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this